Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study

Teli Shaikh Emaran Shaikh Ismail; Jaiprakash Ramanand; Rajshree Netram Mandhare; Chetan Suresh Bhangale

doi:10.5455/njppp.2021.11.05156202105062021

2026, Vol: 16, Issue: 2

16 / 2Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

NJPPP Manuscript Submission Form
Title Page

« Previous Article

Original Research
Online Published: 30 Jul 2021

Natl J Physiol Pharm Pharmacol. 2021; 11(9): 1060-1063

doi: 10.5455/njppp.2021.11.05156202105062021

Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study

Teli Shaikh Emaran Shaikh Ismail, Jaiprakash Ramanand, Rajshree Netram Mandhare, Chetan Suresh Bhangale.

Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (coronavirus disease [COVID-19]) is a global pandemic since December 2019. Cytokine release syndrome is a promising etiology for the severe manifestations of COVID-19. Along with viral invasion of cellular immunity, cytokine storm plays an important role in disease progression. For tackling the immune response, immunomodulators play an important role. Various studies have reported that there has been a decrease in IL-6 level, C-reactive protein (CRP) level, and lower risk of death with the use of tocilizumab in patients with severe COVID-19 disease.

Aims and Objectives: Our study aimed to investigate the association between tocilizumab exposure and outcome among COVID-19 patients in a dedicated COVID hospital. The objectives of the study were to assess the clinical outcome in COVID-19 in terms of death and discharge as well as to compare the total leukocyte count, CRP, lactate dehydrogenase, creatine kinase MB, and D-Dimer before and after the administration of tocilizumab.

Materials and Methods: After obtaining ethics committee approval, we included 41 patients who received injection tocilizumab. After going through all the records, we entered the data in the Microsoft Excel sheet and assessed the data with the use of statistical analysis of Microsoft Excel.

Results: Out of 41 patients, 19 patients were discharged and 22 patients did not survive. The laboratory investigations showed significant improvement after the administration of tocilizumab.

Conclusion: Tocilizumab use has shown improvement in the laboratory investigations, but the clinical outcome did not show significant results.

Key words: Immunomodulators; Tocilizumab; Coronavirus disease

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Teli Shaikh Emaran Shaikh Ismail Articles by Jaiprakash Ramanand Articles by Rajshree Netram Mandhare Articles by Chetan Suresh Bhangale
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Ismail TSES, Ramanand J, Mandhare RN, Bhangale CS. Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study. Natl J Physiol Pharm Pharmacol. 2021; 11(9): 1060-1063.

doi:10.5455/njppp.2021.11.05156202105062021

Web Style

Ismail TSES, Ramanand J, Mandhare RN, Bhangale CS. Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study. https://www.njppp.com/?mno=82774 [Access: June 27, 2026].

doi:10.5455/njppp.2021.11.05156202105062021

AMA (American Medical Association) Style

Ismail TSES, Ramanand J, Mandhare RN, Bhangale CS. Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study. Natl J Physiol Pharm Pharmacol. 2021; 11(9): 1060-1063.

doi:10.5455/njppp.2021.11.05156202105062021

Vancouver/ICMJE Style

Ismail TSES, Ramanand J, Mandhare RN, Bhangale CS. Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study. Natl J Physiol Pharm Pharmacol. (2021), [cited June 27, 2026]; 11(9): 1060-1063.

doi:10.5455/njppp.2021.11.05156202105062021

Harvard Style

Ismail, T. S. E. S., Ramanand, . J., Mandhare, . R. N. & Bhangale, . C. S. (2021) Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study. Natl J Physiol Pharm Pharmacol, 11 (9), 1060-1063.

doi:10.5455/njppp.2021.11.05156202105062021

Turabian Style

Ismail, Teli Shaikh Emaran Shaikh, Jaiprakash Ramanand, Rajshree Netram Mandhare, and Chetan Suresh Bhangale. 2021. Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study. National Journal of Physiology, Pharmacy and Pharmacology, 11 (9), 1060-1063.

doi:10.5455/njppp.2021.11.05156202105062021

Chicago Style

Ismail, Teli Shaikh Emaran Shaikh, Jaiprakash Ramanand, Rajshree Netram Mandhare, and Chetan Suresh Bhangale. "Clinical outcome in coronavirus disease patients treated with tocilizumab at a dedicated COVID hospital: A retrospective observational study." National Journal of Physiology, Pharmacy and Pharmacology 11 (2021), 1060-1063.

doi:10.5455/njppp.2021.11.05156202105062021

MLA (The Modern Language Association) Style

doi:10.5455/njppp.2021.11.05156202105062021

APA (American Psychological Association) Style

doi:10.5455/njppp.2021.11.05156202105062021

About National Journal of Physiology, Pharmacy and Pharmacology

Contact Information

How to cite this article